---
title: "600513.SH (600513.SH) — Related News"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/600513.SH/news.md"
symbol: "600513.SH"
name: "600513.SH"
parent: "https://longbridge.com/en/quote/600513.SH.md"
datetime: "2026-05-20T06:54:20.873Z"
locales:
  - [en](https://longbridge.com/en/quote/600513.SH/news.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/600513.SH/news.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/600513.SH/news.md)
---

# 600513.SH (600513.SH) — Related News

### [JLPC: The holding subsidiary's vitamin injection has received approval for the supplementary application](https://longbridge.com/en/news/285904021.md)
*2026-05-11T08:17:02.000Z*
> JLPC announced that its holding subsidiary ChangLe Pharmaceutical recently received the "Drug Supplement Application App

### [JLPC: The unblinding results of the Phase III monotherapy clinical trial for the new Class 1 drug LH-1801 meet expectations](https://longbridge.com/en/news/285514794.md)
*2026-05-07T08:51:35.000Z*
> JLPC announced that the Phase III clinical trial of its Class 1 new drug LH - 1801 tablets has completed unblinding, and

### [](https://longbridge.com/en/news/285295879.md)
*2026-05-06T01:53:13.000Z*
> The A-share innovative drug sector has fluctuated and strengthened, with TONGHUA GOLDEN-HORSE hitting the daily limit, O

### [JLPC: The primary endpoint of the Phase III clinical trial of the company's Class 1 new drug LH-1801 combined with Metformin meets expectations](https://longbridge.com/en/news/284526029.md)
*2026-04-29T08:47:15.000Z*
> JLPC announced that the Phase III clinical trial of its Class 1 new drug LH-1801 tablets has completed unblinding, and t

### [JLPC: The holding subsidiary plans to invest 300 million yuan to build a pharmaceutical precision cold chain manufacturing center project](https://longbridge.com/en/news/284185233.md)
*2026-04-27T09:22:02.000Z*
> JLPC's subsidiary, Lianhuan Marketing, plans to invest 300 million RMB to build a pharmaceutical precision cold chain ma

### [JLPC: Plans to invest 150 million yuan in the Yangzhou High-tech Industrial Development Zone to build a science and technology innovation center project](https://longbridge.com/en/news/284185221.md)
*2026-04-27T09:21:58.000Z*
> JLPC has signed a contract with the Management Committee of Yangzhou High-tech Industrial Development Zone, planning to 

### [JLPC: Net profit in the first quarter was 6.4248 million yuan, a year-on-year decrease of 72.14%](https://longbridge.com/en/news/284185179.md)
*2026-04-27T09:21:48.000Z*
> JLPC announced that in the first quarter of 2026, operating revenue was 811 million yuan, a year-on-year increase of 29.

### [JLPC: Net profit loss of 98.3324 million yuan in 2025](https://longbridge.com/en/news/283336200.md)
*2026-04-20T10:36:01.000Z*
> JLPC announced that the operating revenue in 2025 is expected to be 2.712 billion yuan, a year-on-year increase of 25.52

### [JLPC: The hydrochloride injection of metoclopramide has obtained the drug registration certificate](https://longbridge.com/en/news/282659144.md)
*2026-04-14T09:01:59.000Z*
> JLPC's subsidiary, Xinxiang Changle Pharmaceutical, recently obtained the "Drug Registration Certificate" for Methochlor